Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) shares hit a new 52-week high during trading on Monday. The company traded as high as $305.14 and last traded at $305.0610, with a volume of 465342 shares trading hands. The stock had previously closed at $290.19.
Wall Street Analysts Forecast Growth
CRL has been the subject of a number of research analyst reports. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a report on Wednesday, July 1st. Barclays increased their price target on Charles River Laboratories International from $300.00 to $330.00 and gave the company an "overweight" rating in a research note on Friday, September 25th. CLSA downgraded shares of Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 price objective on the stock. in a report on Monday, July 20th. Jefferies Financial Group increased their price objective on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the company a "buy" rating in a research report on Monday, September 28th. Finally, Royal Bank Of Canada upped their price target on shares of Charles River Laboratories International from $282.00 to $322.00 and gave the company an "outperform" rating in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $300.11.
Check Out Our Latest Report on CRL
Charles River Laboratories International Price Performance
The firm has a market capitalization of $14.53 billion, a price-to-earnings ratio of -62.93, a P/E/G ratio of 2.70 and a beta of 1.40. The company's 50 day moving average is $277.46 and its 200 day moving average is $217.99. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business's revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.42 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, Director Nancy C. Andrews sold 573 shares of Charles River Laboratories International stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total transaction of $163,442.52. Following the completion of the transaction, the director owned 1,438 shares of the company's stock, valued at $410,175.12. This trade represents a 28.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Birgit Girshick sold 6,500 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the sale, the chief executive officer owned 36,013 shares of the company's stock, valued at approximately $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 90,990 shares of company stock worth $25,731,388. Corporate insiders own 1.30% of the company's stock.
Institutional Trading of Charles River Laboratories International
Several large investors have recently made changes to their positions in CRL. Dimensional Fund Advisors LP raised its stake in Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock worth $285,001,000 after buying an additional 210,260 shares during the period. Bank of America Corp DE raised its position in shares of Charles River Laboratories International by 5.0% during the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company's stock worth $195,792,000 after purchasing an additional 54,500 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of Charles River Laboratories International by 8.7% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 836,240 shares of the medical research company's stock worth $166,813,000 after purchasing an additional 66,803 shares during the period. Amundi lifted its holdings in shares of Charles River Laboratories International by 175.2% in the 1st quarter. Amundi now owns 773,315 shares of the medical research company's stock worth $133,397,000 after purchasing an additional 492,301 shares in the last quarter. Finally, Clearbridge Investments LLC grew its position in Charles River Laboratories International by 23.0% in the 4th quarter. Clearbridge Investments LLC now owns 511,618 shares of the medical research company's stock valued at $102,058,000 after purchasing an additional 95,619 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.
About Charles River Laboratories International
(
Get Free Report)
Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.
Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.
Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Charles River Laboratories International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.
While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
